Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study - Glund, Stephan; Stangier, Joachim; van Ryn, Joanne; Schmohl, Michael; Moschetti, Viktoria; Haazen, Wouter; De Smet, Marina; Gansser, Dietmar; Norris, Stephen; Lang, Benjamin; Reilly, Paul; Kreuzer, Jörg (Clinical pharmacokinetics, 2017)
Keywords: Age; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Anticoagulants; Antithrombins - pharmacology; Area Under Curve; Blood Coagulation - drug effects; Cardiac arrhythmia; Cross-Over Studies; Dabigatran - pharmacology; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Female; Half-Life; Humans; Internal Medicine; Kidney Function Tests; Male; Medicine; Medicine & Public Health; Metabolic Clearance Rate; Middle age; Middle Aged; Monoclonal antibodies; Original; Original Research Article; Partial Thromboplastin Time; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Renal Insufficiency - metabolism; Thromboembolism; Time Factors; Dabigatran Etexilate; Renal Impairment; Dabigatran; Elderly Volunteer; Ecarin Clotting Time